Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2001 1
2004 3
2005 2
2006 4
2007 1
2008 1
2009 2
2013 3
2014 1
2015 2
2016 1
2017 1
2019 2
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma.
Gjerstorff MF, Pøhl M, Olsen KE, Ditzel HJ. Gjerstorff MF, et al. BMC Cancer. 2013 Oct 8;13:466. doi: 10.1186/1471-2407-13-466. BMC Cancer. 2013. PMID: 24103781 Free PMC article.
BACKGROUND: The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of cancer. The MAGE-A3 cancer/testis antigen is frequently expressed in non-small cell lung cancer (NSCLC) and vacc …
BACKGROUND: The unique expression pattern and immunogenic properties of cancer/testis antigens make them ideal targets for immunotherapy of …
Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T. Yoshida N, et al. Int J Oncol. 2006 May;28(5):1089-98. Int J Oncol. 2006. PMID: 16596224
To evaluate the potential of two members of this family, MAGE-A4 and NY-ESO-1 antigens, for cancer vaccine in non-small cell lung carcinoma (NSCLC), we examined the expression of these antigens and T cell infiltration in tumor tissue, and …
To evaluate the potential of two members of this family, MAGE-A4 and NY-ESO-1 antigens, for cancer vaccine in non-small cel …
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Jung EH, Jang HR, Kim SH, Suh KJ, Kim YJ, Lee JH, Chung JH, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Jung EH, et al. Thorac Cancer. 2021 Mar;12(5):619-630. doi: 10.1111/1759-7714.13834. Epub 2021 Jan 17. Thorac Cancer. 2021. PMID: 33458968 Free PMC article.
BACKGROUND: Immune checkpoint inhibitors (ICIs) are an established treatment for non-small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). ...
BACKGROUND: Immune checkpoint inhibitors (ICIs) are an established treatment for non-small cell lung cancer (NSC …
Reverse Vaccinology Approach in Constructing a Multi-Epitope Vaccine Against Cancer-Testis Antigens Expressed in Non-Small Cell Lung Cancer.
Herrera LRM. Herrera LRM. Asian Pac J Cancer Prev. 2021 May 1;22(5):1495-1506. doi: 10.31557/APJCP.2021.22.5.1495. Asian Pac J Cancer Prev. 2021. PMID: 34048178 Free PMC article.
BACKGROUND: The 5-year survival rate of non-small cell lung cancer (NSCLC) patients has not significantly improved despite advancements in the currently applied treatments. ...This work utilized reverse vaccinology approach in designing a novel multi-e …
BACKGROUND: The 5-year survival rate of non-small cell lung cancer (NSCLC) patients has not significantly improv …
Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C, Xu Y, Li X, Ren S, Zhao C, Hou L, Ye Z, Zhou C. Su C, et al. Int J Clin Exp Pathol. 2015 May 1;8(5):5509-18. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26191258 Free PMC article.
Nowadays, there is still no predictive biomarker identified for the use of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) patients. To clarify the role of CD133 and CTAs as a predictive marker for adjuvant chemotherapy or prognostic factor …
Nowadays, there is still no predictive biomarker identified for the use of adjuvant chemotherapy in non-small cell l …
Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Wang H, Xia Y, Yu J, Guan H, Wu Z, Ban D, Wang M. Wang H, et al. HLA. 2019 Jul;94(1):39-48. doi: 10.1111/tan.13547. Epub 2019 Apr 30. HLA. 2019. PMID: 30953385
T-cell receptor (TCR)-engineered T cells targeting New York esophageal squamous cell carcinoma 1 (NY-ESO-1) have been employed in a number of clinical trials for late stage melanoma, synovial sarcoma, multiple myeloma and other malignancies. Owing to the sign …
T-cell receptor (TCR)-engineered T cells targeting New York esophageal squamous cell carcinoma 1 (NY-ESO-1) have been e …
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A. Papachristofilou A, et al. J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5. J Immunother Cancer. 2019. PMID: 30736848 Free PMC article. Clinical Trial.
BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung cancer (NSCLC)-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, and MUC-1), intended to in …
BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non- …
The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
John T, Starmans MH, Chen YT, Russell PA, Barnett SA, White SC, Mitchell PL, Walkiewicz M, Azad A, Lambin P, Tsao MS, Deb S, Altorki N, Wright G, Knight S, Boutros PC, Cebon JS. John T, et al. PLoS One. 2013 Jul 23;8(7):e67876. doi: 10.1371/journal.pone.0067876. Print 2013. PLoS One. 2013. PMID: 23935846 Free PMC article.
BACKGROUND: Cancer-Testis Antigens (CTAs) are immunogenic proteins that are poor prognostic markers in non-small cell lung cancer (NSCLC). We investigated expression of CTAs in NSCLC and their association with response to chemotherapy, genetic mutation …
BACKGROUND: Cancer-Testis Antigens (CTAs) are immunogenic proteins that are poor prognostic markers in non-small cell …
Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
Hanagiri T, Shigematsu Y, Shinohara S, Takenaka M, Oka S, Chikaishi Y, Nagata Y, Baba T, Uramoto H, So T, Yamada S. Hanagiri T, et al. Anticancer Res. 2013 May;33(5):2123-8. Anticancer Res. 2013. PMID: 23645764
AIM: The purpose of this study was to investigate the clinical significance of expression of cancer/testis (CT) antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer (NSCLC), which underwent complete surgical re …
AIM: The purpose of this study was to investigate the clinical significance of expression of cancer/testis (CT) antigen and down-regulation …
Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J, Samija M, Juretić A, Sarcević B, Sobat H. Grah J, et al. Coll Antropol. 2008 Sep;32(3):731-6. Coll Antropol. 2008. PMID: 18982744
The study included 80 patients with non-small cell lung cancer (40 adenocarcinomas, 40 squamous cell carcinomas) who had undergone surgery in the period between 2002 and 2005. ...A statistically significant association was noted between the NY-E …
The study included 80 patients with non-small cell lung cancer (40 adenocarcinomas, 40 squamous cell carc …
27 results